look into the abyss of biotechnology Twitter and find a bush of obtuse acronyms, abbreviations confusing, and a strange propensity for using dollar signs as hashtags. But in this expansion are some of the main authors of 140 characters that allow to know the most important, the clarity and context for those hoping to understand the rapidly growing industry of drug development.
Sometimes they are even fun.
We have developed a list of 10 foods such enlightening for BioCurious. Important note: We have left out to great many journalists should probably be as follows. We have also omitted some of the entrepreneurs and commentators that have thousands of followers as is. That’s not a light; We estimate that only those who are already on their radar.
The article continues after the announcement
Instead, here are some interesting, though lesser known, signposts of the vibrant community of Twitter biotechnology.
guru mystery: @andybiotech
There are a large number of anonymous investors on Twitter biotechnology, screaming up or down in several security companies their avatars egg. But none is as AndyBiotech, whoever he or she is. With a comprehensive knowledge of the industry and its many players, Andy provides the context for readings of key data points underreported news, and combs through documents of interesting facts.
The witty Brit: @maverickNY
Sally Church is a cheerful nerd tweeting out incisive observations of the biotechnology industry, providing an analysis more detailed about its usefulness, but expensive Biotech Strategy Blog . The marketer of life science alum become Novartis is a fan of good science, but is not afraid to call BS when he sees it. – Especially when it comes to their field of expertise, oncology
The legal mind: @jsherkow
Patents are important in biotechnology, such as multimillion last fight suggests. And Jacob Sherkow, professor at the Faculty of Law, New York, is an expert in the field. Look at it for the context of recent disputes over biosimilars, reflections on the legal implications of data exchange, and tweetstorms on the future of CRISPR.
The regulatory expert: @fdaadcomm
The murky waters of regulatory policy are enormous for some – but not for Jessica Adams, who ardently track the comings and goings of the scientific advisory committees and Drug Administration food as part of their concert as a consultant for Tario, a research team regulators. Theirs is a low-cost account that will keep you abreast of day priorities long-winded, but most importantly the FDA for the day -. In 140 characters
The scientific nitpicker: @ VinayPrasad82
Let’s all admit it: the Biopharma data can be divided in a way that is often overly flattering – especially when it comes to survival rates for cancer. Dr. Vinay Prasad, a hematologist-oncologist in Oregon, uses his Twitter account to cut through the essence of what is presented in a clinical trial or academic article. Do not argue with him in progression-free survival. He school.
David Grainger, partner biotechnology investor Medicxi Ventures, hastens to lift a finger in the last fed bombo- do in biotechnology. From its position in the UK, which pokes holes in the widely publicized studies, dispels myths about biotechnology convenient and regrets misleading jargon companies use to influence public opinion.
The rockstar VC: @lifescivc
If only venture capitalists life sciences were as transparent as Bruce Booth. A robust, really, biotechnology blogosfera , Atlas Ventures, VC (and “scientific recover”) is a useful source of information and updates on the life sciences investment at early stage. Sometimes your comment bioscience is scored with quotes from luminaries such as Ansel Adams, Christopher Hitchens, and Metallica.
Number Cruncher: @maxjacobsedison
Biotech is a company, after all, and companies are supposed to make money. But amidst all the hype of unmet needs and futuristic science, many drug developers are burning quietly the candle at both ends. Maxim Jacobs, head of health research in Edison, is a professional in digging through the mud of financial reporting and asking key questions such as: “Should not this company in bankruptcy?”
The individualist investor: @bradloncar
there to Located in Kansas City, Brad Loncar view private investor is not afraid to make skeptical and stubborn view the biotechnology industry. It is noteworthy that it is built an index of cancer immunotherapy , and tracks the performance of 30 large biotech companies and cap growth in that space. In a previous life, Loncar worked in politics.
The contrary: @zbiotech
Speaking of those anonymous investors, here’s one more. Zach, as he is known on Twitter, is lightning fast to tweet breaking news, but does so with a heavy pile of sarcasm, skepticism and disdain for the sweet optimism that sometimes springs from the mouths of executives Biotechnology .